Toll Free: 1-888-928-9744

Glaukos Corporation (GKOS) - Product Pipeline Analysis, 2016 Update

Published: Jun 22, 2016 | Pages: 45 | Publisher: GlobalData | Industry: Medical Devices | Report Format: Electronic (PDF)

Summary

Glaukos Corporation (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company's products include microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Its iStent is used in conjunction with cataract surgery. Glauko's iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm's canal. It markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France. Glaukos is headquartered in Laguna Hills, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.  

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Glaukos Corporation
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 6 Glaukos Corporation Company Snapshot 7 Glaukos Corporation Company Overview 7 Glaukos Corporation Pipeline Products and Clinical Trials Overview 8 Glaukos Corporation - Pipeline Analysis Overview 10 Key Facts 10 Glaukos Corporation - Major Products and Services 11 Glaukos Corporation Pipeline Products by Development Stage 12 Glaukos Corporation Clinical Trials by Trial Status 14 Glaukos Corporation Pipeline Products Overview 17 GTS400 17 GTS400 Product Overview 17 iDose Travoprost Intraocular Implant 18 iDose Travoprost Intraocular Implant Product Overview 18 iDose Travoprost Intraocular Implant Clinical Trial 19 iStent Inject - Cataract Surgery 20 iStent Inject - Cataract Surgery Product Overview 20 iStent Inject - Cataract Surgery Clinical Trial 21 iStent Inject - Standalone Procedures 22 iStent Inject - Standalone Procedures Product Overview 22 iStent Supra 23 iStent Supra Product Overview 23 iStent Supra Clinical Trial 24 iStent Trabecular Micro-Bypass Stent 25 iStent Trabecular Micro-Bypass Stent Product Overview 25 iStent Trabecular Micro-Bypass Stent Clinical Trial 26 Glaukos Corporation - Key Competitors 34 Glaukos Corporation - Key Employees 35 Glaukos Corporation - Locations And Subsidiaries 36 Head Office 36 Recent Developments 37 Glaukos Corporation, Recent Developments 37 May 03, 2016: Glaukos Announces First Quarter 2016 Financial Results 37 Apr 28, 2016: Glaukos Technologies Featured In Numerous Presentations At 2016 American Society Of Cataract And Refractive Surgery 37 Apr 14, 2016: Glaukos Announces Retirement Of Olav Bergheim From Board Of Directors 39 Mar 28, 2016: Glaukos iStent Trabecular Micro-Bypass Stent Approved in Japan 40 Mar 01, 2016: Glaukos Announces Fourth Quarter & Full Year 2015 Financial Results 40 Feb 08, 2016: Glaukos Establishes Direct Sales Organization and Launches iStent inject Trabecular Micro-Bypass Stent in Australia 41 Feb 01, 2016: Glaukos Launches New Direct Sales Organization and Begins Commercialization of iStent inject Trabecular Micro-Bypass Stent in Canada 42 Jan 20, 2016: International Study Shows 3-Year Benefits of Glaukos iStent Trabecular Micro-Bypass Stent in Combination with Cataract Surgery 43 Jan 12, 2016: Glaukos Provides Preliminary Fourth Quarter and Full Year 2015 Net Sales and Full Year 2016 Net Sales Guidance 44 Jan 07, 2016: Glaukos Will Begin Phase II Clinical Trial For Idose Travoprost Intraocular Implant In Glaucoma Patients 44 Appendix 45 Methodology 45 About GlobalData 45 Contact Us 45 Disclaimer 45
List of Tables
Glaukos Corporation Pipeline Products and Clinical Trials Overview 8 Glaukos Corporation Pipeline Products by Equipment Type 8 Glaukos Corporation Pipeline Products by Indication 9 Glaukos Corporation Clinical Trials by Trial Status 9 Glaukos Corporation, Key Facts 10 Glaukos Corporation, Major Products and Services 11 Glaukos Corporation Number of Pipeline Products by Development Stage 12 Glaukos Corporation Pipeline Products Summary by Development Stage 13 Glaukos Corporation Clinical Trials by Trial Status 14 Glaukos Corporation Clinical Trials Summary 15 GTS400 - Product Status 17 GTS400 - Product Description 17 iDose Travoprost Intraocular Implant - Product Status 18 iDose Travoprost Intraocular Implant - Product Description 18 iDose Travoprost Intraocular Implant - Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure 19 iStent Inject - Cataract Surgery - Product Status 20 iStent Inject - Cataract Surgery - Product Description 20 iStent Inject - Cataract Surgery - A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 21 iStent Inject - Cataract Surgery - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 21 iStent Inject - Standalone Procedures - Product Status 22 iStent Inject - Standalone Procedures - Product Description 22 iStent Supra - Product Status 23 iStent Supra - Product Description 23 iStent Supra - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated with One Suprachoroidal Stent 24 iStent Supra - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 24 iStent Trabecular Micro-Bypass Stent - Product Status 25 iStent Trabecular Micro-Bypass Stent - Product Description 25 iStent Trabecular Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment with One or Two Trabecular Micro-bypass Stents in Conjunction with Cataract Surgery 26 iStent Trabecular Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated with Two Trabecular Micro-bypass Stents 26 iStent Trabecular Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 27 iStent Trabecular Micro-Bypass Stent - A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery 27 iStent Trabecular Micro-Bypass Stent - A Prospective, Multicenter, Randomized Comparison of the Hydrus to the iStent for Lowering Intraocular Pressure in Primary Open Angle Glaucoma 28 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 28 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated with Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% 29 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized, Controlled Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted with One, Two, or Three Trabecular Micro-bypass Stents 29 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized, Controlled Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted with One, Two, Or Three Trabecular Micro-bypass Stents 30 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized, Controlled, Parallel Groups Evaluation of Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment with Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty 30 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized, Controlled, Parallel Groups, Multi-center Post-Approval Study Of The Glaukos iStent Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery 31 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multi-center Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 In Conjunction with Cataract Surgery 31 iStent Trabecular Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 32 iStent Trabecular Micro-Bypass Stent - Glaukos iStent Trabecular Micro-Bypass Stent System In Conjunction with Cataract Surgery Postmarket Registry 32 iStent Trabecular Micro-Bypass Stent - International Study of iStent in Phakic and Pseudophakic Glaucoma Patients 33 iStent Trabecular Micro-Bypass Stent - Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty 33 Glaukos Corporation, Key Employees 35


List of Figures
Glaukos Corporation Pipeline Products by Equipment Type 9 Glaukos Corporation Pipeline Products by Development Stage 12 Glaukos Corporation Clinical Trials by Trial Status 14

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...
Choose License Type
Single User - US $750
Multi User - US $1500
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify